Selvom sensitivitetsanalyser viser, at forskelle i behandlingsskemaer og tidspunkt for tumorvurdering påvirker analysen for progressionsfri overlevelse on- treatment, er der ikke fundet en fyldestgørende forklaring på dette fund.
Although sensitivity analyses show that differences in regimen schedules and timing of tumor assessments impact the on- treatment PFS analysis, a full explanation for this result has not been found.